Annabel Samimy
Stock Analyst at Stifel
(4.42)
# 288
Out of 5,173 analysts
57
Total ratings
46.3%
Success rate
37.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $40 → $50 | $24.60 | +103.25% | 3 | Mar 5, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $17 | $4.68 | +263.25% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $10.76 | +67.29% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $49.25 | +11.68% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $8.34 | +439.57% | 3 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $23.65 | +119.87% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $28.14 | +77.68% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $17.57 | +173.19% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $200.36 | +14.79% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $49.06 | +83.45% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $117.04 | +23.89% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.44 | +423.26% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $6.08 | +179.61% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.20 | +119.51% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $10.57 | +127.06% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $32.55 | +145.78% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $182.32 | +26.15% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.14 | +2,005.26% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.31 | +32,367.53% | 3 | Apr 16, 2020 |
Oculis Holding AG
Mar 5, 2026
Maintains: Buy
Price Target: $40 → $50
Current: $24.60
Upside: +103.25%
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $4.68
Upside: +263.25%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $10.76
Upside: +67.29%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $49.25
Upside: +11.68%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $8.34
Upside: +439.57%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $23.65
Upside: +119.87%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $28.14
Upside: +77.68%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $17.57
Upside: +173.19%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $200.36
Upside: +14.79%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $49.06
Upside: +83.45%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $117.04
Upside: +23.89%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.44
Upside: +423.26%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $6.08
Upside: +179.61%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.20
Upside: +119.51%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $10.57
Upside: +127.06%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $32.55
Upside: +145.78%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $182.32
Upside: +26.15%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.14
Upside: +2,005.26%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.31
Upside: +32,367.53%